Continuing Education Improving Outcomes for Patients with Myelofibrosis: A Case-based Analysis John O. Mascarenhas, MD and Sandra Kurtin, PhD, ANP-C, AOCN, FAPO

Continuing Education Beyond Ruxolitinib as the Frontline Standard of Care: Current and Emerging Second-Line Therapies Prithviraj Bose, MD; and Andrew Kuykendall, MD

Continuing Education Defining Disease Response and Progression: Treatment Resistance, Failure and/or Loss of Response Prithviraj Bose, MD; and John Mascarenhas, MD

FAQ Other than cytopenias, what are signs that my patient is intolerant to ruxolitinib or a JAK inhibitor? Sandra Kurtin, PhD, ANP-C, AOCN, FAPO

FAQ What are the updates from ASH regarding new treatments or new data for patients with myelofibrosis? John O. Mascarenhas, MD

What are MPNs? What are Myeloproliferative neoplasms (MPNs)?

FAQ Can we predict which patients will respond to a JAK inhibitor? Andrew Kuykendall, MD and Prithviraj Bose, MD

FAQ How would you define treatment success for your patients with myelofibrosis? Andrew Kuykendall, MD and Prithviraj Bose, MD

FAQ As a clinician, what should guide my decision on which second-line therapy to choose for my patients? Prithviraj Bose, MD

FAQ What key defining point should community providers be aware of when looking at patients considered to have failed ruxolitinib or have achieved only suboptimal response? John Mascarenhas, MD View all FAQs